CoChat

Methylphenidate Decreased the Amount of Glucose Needed by the Brain to Perform a Cognitive Task

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

The use of stimulants (methylphenidate and amphetamine) as cognitive enhancers by the general public is increasing and is controversial. It is still unclear how they work or why they improve performance in some individuals but impair it in others. To test the hypothesis that stimulants enhance signal to noise ratio of neuronal activity and thereby reduce cerebral activity by increasing efficiency, we measured the effects of methylphenidate on brain glucose utilization in healthy adults. We measured brain glucose metabolism (using Positron Emission Tomography and 2-deoxy-2[18F]fluoro-D-glucose) in 23 healthy adults who were tested at baseline and while performing an accuracy-controlled cognitive task (numerical calculations) given with and without methylphenidate (20 mg, oral). Sixteen subjects underwent a fourth scan with methylphenidate but without cognitive stimulation. Compared to placebo methylphenidate significantly reduced the amount of glucose utilized by the brain when performing the cognitive task but methylphenidate did not affect brain metabolism when given without cognitive stimulation. Whole brain metabolism when the cognitive task was given with placebo increased 21% whereas with methylphenidate it increased 11% (50% less). This reflected both a decrease in magnitude of activation and in the regions activated by the task. Methylphenidate's reduction of the metabolic increases in regions from the default network (implicated in mind-wandering) was associated with improvement in performance only in subjects who activated these regions when the cognitive task was given with placebo. These results corroborate prior findings that stimulant medications reduced the magnitude of regional activation to a task and in addition document a "focusing" of the activation. This effect may be beneficial when neuronal resources are diverted (i.e., mind-wandering) or impaired (i.e., attention deficit hyperactivity disorder), but it could be detrimental when brain activity is already optimally focused. This would explain why methylphenidate has beneficial effects in some individuals and contexts and detrimental effects in others.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0002017

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of experimental procedure. Placebo (PL) or methylphenidate (MP) was given 60 minutes prior to initiation of Cognitive or Neutral tasks, which lasted 45 minutes. [18F]FDG was injected 15 minutes after task initiation (75 minutes after MP or PL) and scans were started 35 minutes after injection.
Figure 1 Schematic diagram of experimental procedure. Placebo (PL) or methylphenidate (MP) was given 60 minutes prior to initiation of Cognitive or Neutral tasks, which lasted 45 minutes. [18F]FDG was injected 15 minutes after task initiation (75 minutes after MP or PL) and scans were started 35 minutes after injection.CC0 · PubMed Central
Figure 2 Brain activation with the task after placebo (PL) and after methylphenidate (MP). A. SPM results showing the areas that had increases in metabolism for the cognitive task with placebo versus the control conditions; B. SPM results showing the areas that had increases in metabolism for the cognitive task with MP versus the control conditions. Comparisons correspond to paired t tests (p<0.001 uncorrected >100 pixels). None of the brain regions had higher metabolism for the control condition (neutral non-task with placebo) than for the cognitive task conditions.
Figure 2 Brain activation with the task after placebo (PL) and after methylphenidate (MP). A. SPM results showing the areas that had increases in metabolism for the cognitive task with placebo versus the control conditions; B. SPM results showing the areas that had increases in metabolism for the cognitive task with MP versus the control conditions. Comparisons correspond to paired t tests (p<0.001 uncorrected >100 pixels). None of the brain regions had higher metabolism for the control condition (neutral non-task with placebo) than for the cognitive task conditions.CC0 · PubMed Central
Figure 3 Differences in task activation between placebo (PL) and methylphenidate (MP). SPM results showing the areas that had greater increases in metabolism when the cognitive task was given with placebo versus when it was given with methylphenidate (MP). Comparisons correspond to paired t-tests (p<0.005 uncorrected >100 pixels). None of the brain regions had higher metabolism for the cognitive task when given with MP than with placebo.
Figure 3 Differences in task activation between placebo (PL) and methylphenidate (MP). SPM results showing the areas that had greater increases in metabolism when the cognitive task was given with placebo versus when it was given with methylphenidate (MP). Comparisons correspond to paired t-tests (p<0.005 uncorrected >100 pixels). None of the brain regions had higher metabolism for the cognitive task when given with MP than with placebo.CC0 · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 117

Metadata

Authors
Volkow, N. D., Fowler, J. S., Wang, G.-J., Telang, F., Logan, J., Wong, C., Ma, J., Pradhan, K., Benveniste, H., & Swanson, J. M.
Affiliations
  • National Institute on Drug Abuse (US)
  • Brookhaven National Laboratory (US)
  • National Institute on Alcohol Abuse and Alcoholism (US)
  • University of California, Irvine (US)
Corresponding author
Volkow, Nora D.
Venue
PLoS ONE
Published
2008-04-16
Volume
3
Issue
4
Pages
e2017
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2099355488
Cited by
117
References
37
Citations by year
2026: 1 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 4 · 2018: 6 · 2017: 4 · 2016: 9 · 2015: 9 · 2014: 7 · 2013: 9 · 2012: 8
FWCI
4.65
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Energy (76CH00016, DE-AC01-76CH00016)
  • National Institutes of Health (DE-AC01-76CH00016)
  • Biological and Environmental Research
Topics
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
methylphenidate, stimulants, brain glucose metabolism, cognitive enhancement, default mode network, mind wandering, signal-to-noise ratio, brain activation, attention deficit hyperactivity disorder, 2-deoxy-2-[18F]fluoro-D-glucose
MeSH terms
Adult, Central Nervous System Stimulants, Brain, Cognition, Female, Glucose, Humans, Male, Methylphenidate, Models, Theoretical, Placebos, Reproducibility of Results, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.